Insights

Royalty Revenue Leverage Enanta's established royalty streams from AbbVie-licensed HCV treatment Mavyret/Maviret to explore co-development or milestone-sharing opportunities, potentially funding expansion into immunology and viral programs.

RSV Pipeline Target partnerships around zelicapavir and other RSV programs to accelerate clinical development, given ongoing presentations and data generation at major conferences, signaling near-term commercialization potential.

Immunology Expansion Position as a collaborator for immunology indications by offering access to Enanta’s KIT, STAT6, and MRGPRX2 inhibitor programs, aligning with firms seeking novel small molecule strategies in type 2 immune responses.

Early Stage Platform Capitalize on Enanta’s chemistry-driven discovery platform to propose joint discovery collaborations or in-licensing deals for preclinical assets, particularly in virology and inflammatory diseases.

Strategic Partnerships Propose value-added collaborations with Enanta to expand reach in global markets through co-commercial or territory-sharing agreements, leveraging their royalty-backed revenue base and ongoing clinical readouts.

Similar companies to Enanta Pharmaceuticals

Enanta Pharmaceuticals Tech Stack

Enanta Pharmaceuticals uses 8 technology products and services including LinkedIn Recruiter, SAS, Adobe Experience Cloud, and more. Explore Enanta Pharmaceuticals's tech stack below.

Media & News

Enanta Pharmaceuticals's Email Address Formats

Enanta Pharmaceuticals uses at least 4 email formats:
Enanta Pharmaceuticals Email FormatsExamplePercentage
FLast@enanta.comJDoe@enanta.com
84%
First.Last@enanta.comJohn.Doe@enanta.com
9%
Last@enanta.comDoe@enanta.com
5%
FirstLast@enanta.comJohnDoe@enanta.com
2%

Frequently Asked Questions

What is Enanta Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals is a publicly traded company; the company's stock symbol is ENTA.

What is Enanta Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals's official website is enanta.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Enanta Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of October 2026, Enanta Pharmaceuticals's annual revenue is estimated to be $50M - $100M.

What is Enanta Pharmaceuticals's SIC code and NAICS code?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Enanta Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of October 2026, Enanta Pharmaceuticals has approximately 146 employees across 3 continents, including North America, Asia and Europe. Key team members include Chief Executive Officer And President: J. L., Vice President Clinical Operations: K. S. and Non-Executive Chairman: B. C. Explore Enanta Pharmaceuticals's employee directory with LeadIQ.

What industry does Enanta Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Enanta Pharmaceuticals use?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals's tech stack includes LinkedIn Recruiter, SAS, Adobe Experience Cloud, Mimecast, Microsoft Dynamics, OpenAI, WP Engine and Adobe Creative Suite.

What is Enanta Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals's email format typically follows the pattern of FLast@enanta.com. Find more Enanta Pharmaceuticals email formats with LeadIQ.

How much funding has Enanta Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of October 2026, Enanta Pharmaceuticals has raised $159M in funding. The last funding round occurred on Sep 30, 2025 for $75M.

When was Enanta Pharmaceuticals founded?

Minus sign iconPlus sign icon
Enanta Pharmaceuticals was founded in 1995.
Enanta Pharmaceuticals logo

Enanta Pharmaceuticals

Biotechnology ResearchMassachusetts, United States51-200 Employees

Enanta Pharmaceuticals is a biotechnology research company headquartered at 4 Kingsbury Avenue in Watertown, Massachusetts. The firm employs between 51 and 200 people and pursues small molecule drug discovery with a chemistry-centric approach, focusing on virology and immunology. Its clinical programs are centered on respiratory syncytial virus (RSV), while its early-stage immunology pipeline targets inflammatory diseases by inhibiting key drivers of the type 2 immune response, including KIT, STAT6, and MRGPRX2. Glecaprevir, a protease inhibitor discovered by Enanta, is used in hepatitis C treatment regimens and marketed by AbbVie as MAVYRET in the United States and MAVIRET elsewhere, with royalties from these products providing ongoing funding to Enanta. The company has ongoing research and development activities including the KIT inhibitor EDP-978 in Phase 1 for urticaria, and zelicapavir, an oral RSV N-protein inhibitor evaluated in Phase IIb, along with a launched STAT6 inhibitor program.

Section iconCompany Overview

Website
enanta.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ENTA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1995
Employees
51-200

Section iconFunding & Financials

  • $159M

    Enanta Pharmaceuticals has raised a total of $159M of funding over 9 rounds. Their latest funding round was raised on Sep 30, 2025 in the amount of $75M as a Post IPO Equity.

  • $50M - $100M

    Enanta Pharmaceuticals's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.